

**IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA  
CLARKSBURG DIVISION**

REGENERON PHARMACEUTICALS, INC.,

Plaintiff,

v.

MYLAN PHARMACEUTICALS INC.,

Defendant.

Case No. 1:22-cv-00061-TSK

**JURY TRIAL DEMANDED**

**REGENERON'S STIPULATION REGARDING  
SUMMARY JUDGMENT AND CASE NARROWING**

On April 20, 2023, Mylan moved for summary judgment of certain claims in U.S. Patent Nos. 10,888,601, 11,084,865, 11,253,572 and 11,104,715 (ECF 429).

Subject to all appellate rights, including but not limited to rights of appeal concerning claim construction, Regeneron does not oppose summary judgment as to the following claims, under the Court's Claim Construction (ECF 427), on the following bases:

- Regeneron accepts summary judgment of noninfringement of claims 2-3, 6, 12-14, and 16 of U.S. Patent No. 11,104,715.
- Regeneron accepts summary judgment of invalidity of claims 5-6 and 9 of U.S. Patent No. 10,888,601.
- Regeneron accepts summary judgment of invalidity of claims 1-5, 8-11, 14, and 26-28 of U.S. Patent No. 11,253,572.

Regeneron opposes summary judgment with respect to all other bases and all other claims that are the subject of Mylan's motion, and will file an opposition to Mylan's motion accordingly.

Pursuant to the Court's Scheduling Order (ECF 87), Regeneron hereby narrows these initial proceedings to the following patents and claims:

1. U.S. Patent No. 10,888,601: Claims 11, 19, and 27
2. U.S. Patent No. 11,084,865: Claims 4, 7, 9, 11, and 14-18
3. U.S. Patent No. 11,253,572: Claims 6, 7, 12, 13, 18, 19, 22, 23, and 25

Date: April 26, 2023

CAREY DOUGLAS KESSLER & RUBY, PLLC

*Of Counsel:*

David I. Berl (admitted *PHV*)  
Ellen E. Oberwetter (admitted *PHV*)  
Thomas S. Fletcher (admitted *PHV*)  
Andrew V. Trask (admitted *PHV*)  
Teagan J. Gregory (admitted *PHV*)  
Shaun P. Mahaffy (admitted *PHV*)  
Sean M. Douglass (admitted *PHV*)  
Kathryn S. Kayali (admitted *PHV*)  
Arthur J. Argall III (admitted *PHV*)  
Adam Pan (admitted *PHV*)  
Nicholas Jordan (admitted *PHV*)  
Haylee N. Bernal Anderson (admitted *PHV*)  
Renee M. Griffin (admitted *PHV*)  
Rebecca Carter (admitted *PHV*)

/s/ Steven R. Ruby

Steven R. Ruby (WVSB No. 10752)  
David R. Pogue (WVSB No. 10806)  
707 Virginia Street East  
901 Chase Tower (25301)  
P.O. Box 913  
Charleston, West Virginia 25323  
(304) 345-1234  
sruby@cdkrlaw.com  
drpogue@cdkrlaw.com

WILLIAMS & CONNOLLY LLP  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
dberl@wc.com  
eoberwetter@wc.com  
tfletcher@wc.com  
atrask@wc.com  
tgregory@wc.com  
smahaffy@wc.com  
sdouglass@wc.com  
kkayali@wc.com  
aargall@wc.com

apan@wc.com  
njordan@wc.com  
handerson@wc.com  
rgriffin@wc.com  
rebeccacarter@wc.com

Andrew E. Goldsmith (admitted PHV)  
Evan T. Leo (admitted PHV)  
Jacob E. Hartman (admitted PHV)  
Mary Charlotte Y. Carroll (admitted PHV)  
Sven E. Henningson (admitted PHV)

KELLOG, HANSEN, TODD, FIGEL &  
FREDERICK, P.L.L.C.  
1615 M Street, N.W., Suite 400  
Washington, D.C. 20036  
TEL: (202) 326-7900  
agoldsmith@kellogghansen.com  
eleo@kellogghansen.com  
jhartman@kellogghansen.com  
Mcarroll@kellogghansen.com  
shenningson@kellogghansen.com

*Counsel for Plaintiff Regeneron Pharmaceuticals, Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that on April 26, 2023, the foregoing was served on Mylan's counsel of record via email because the filing function of the Court's CM/ECF system was unavailable. I further certify that on April 27, 2023, after the issue with the CM/ECF system was resolved, the foregoing was electronically filed with the Clerk of the Court via the Court's CM/ECF system, which will serve counsel of record for all parties.

/s/ Steven R. Ruby

Steven R. Ruby (WVSB No. 10752)